Business Context and Reporting Period
This Form 8-K was filed by Aptevo Therapeutics Inc. on April 23, 2019, reporting an event that occurred on April 18, 2019. The Company is a Delaware corporation headquartered in Seattle, Washington, and is classified as an emerging growth company.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
The material change reported is the receipt of a notification from the Nasdaq Stock Market listing qualifications department. The notification states that for the last 30 consecutive business days, the closing bid price of the Company's common stock has been below $1.00 per share, failing to meet the minimum requirement under Nasdaq listing rule 5450(a)(1).
Outlook, Risks, and Management Commentary
- Compliance Timeline: The Company has 180 calendar days, until October 15, 2019, to regain compliance. This requires the closing bid price to be at least $1.00 per share for a minimum of ten consecutive business days prior to the deadline.
- Contingency Plan: If compliance is not achieved by October 15, 2019, the Company may apply to transfer its listing to the Nasdaq Capital Market for an additional 180-day period. This requires meeting market value and other initial listing standards, potentially necessitating a reverse stock split.
- Risks: If the Company fails to cure the deficiency or meet other listing standards, Nasdaq may issue a delisting notice. The Company retains the right to appeal any delisting determination to a Hearings Panel.
- Management Action: Management intends to actively monitor the stock price and evaluate available options to resolve the deficiency.
Investor Verification Checklist
- Verify the current closing bid price of Aptevo Therapeutics Inc. common stock to assess progress toward the $1.00 threshold.
- Monitor for any announcements regarding a reverse stock split or transfer application to the Nasdaq Capital Market.
- Check for any subsequent correspondence from Nasdaq regarding the status of the delisting risk or extension of the compliance period.
- Review the Company's market value of publicly held shares to ensure eligibility for the Nasdaq Capital Market if a transfer is pursued.